Activist Starboard buys more Salesforce stock after first demanding change in 2022

Activist investor Starboard Value significantly increased its stake in Salesforce by nearly 50% to 1.3 million shares in Q2, signaling potential renewed activist pressure on the software company, which has seen its stock decline almost 30% year-to-date. Concurrently, Starboard boosted its Pfizer holding by 10.5% while reducing its Autodesk stake by 27% following a settled dispute. These portfolio adjustments, revealed in a regulatory filing, indicate Starboard's strategic re-engagement with underperforming assets and shifts in its activist positions.

Analysis

Activist investor Starboard Value has significantly increased its exposure to Salesforce (CRM), raising its stake by nearly 50% to 1.3 million shares as of the end of the second quarter. This move follows a 52% increase in the prior quarter and re-establishes pressure on the software company, whose stock has declined approximately 30% year-to-date. The renewed accumulation is particularly notable given that many other activists who engaged Salesforce in late 2022 and early 2023 liquidated their positions after the company implemented operational and governance changes that led to a near 100% stock price gain in 2023. Starboard's action, consistent with its strategy of revisiting companies perceived as backsliding, suggests a belief that further value can be unlocked, aligning with CEO Jeffrey Smith's late-2023 commentary on Salesforce's potential for greater efficiency and profitability. Concurrent portfolio adjustments, including a 10.5% increase in its Pfizer (PFE) holding and a 27% reduction in its Autodesk (ADSK) stake following a settlement, underscore a strategic reallocation of capital towards its highest-conviction activist campaigns.

Key Decisions for Investors

• Investors in Salesforce (CRM) should view Starboard's increased stake as a potential near-term catalyst, and monitor closely for any new strategic demands or management responses aimed at addressing the stock's recent underperformance.
• Given Starboard's stated focus on efficiency, market participants should anticipate renewed pressure on Salesforce to improve margins and operational discipline, which could introduce volatility but also create a pathway for a valuation re-rating.
• Starboard's decision to trim its Autodesk (ADSK) stake post-settlement while adding to Pfizer (PFE) signals a shift in its activist priorities, suggesting investors in those companies should weigh the impact of a key activist either reducing or increasing their conviction.